YIH
ENTA icon

Y-Intercept (HK)’s Enanta Pharmaceuticals ENTA Stock Holding History

Y-Intercept (HK)’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-45,999
Closed -$597K – 1447
2024
Q2 		$597K Buy
+45,999
New +$621K 0.03% 740
2023
Q4 		– Sell
-31,247
Closed -$349K – 1345
2023
Q3 		$349K Buy
+31,247
New +$503K 0.03% 701
2023
Q2 		– Sell
-5,436
Closed -$220K – 1382
2023
Q1 		$220K Buy
5,436
+1,051
+24% +$50.2K 0.03% 919
2022
Q4 		$204K Buy
+4,385
New +$200K 0.03% 829

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s ENTA Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Enanta Pharmaceuticals (ENTA) in Q3 2024, closing a stake of 45,999 shares — an estimated $597K sold.

Y-Intercept (HK) first reported a position in ENTA in Q4 2022 and held it in 4 quarters. The position peaked at $597K in Q2 2024. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Enanta Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 45,999 Enanta Pharmaceuticals shares in Q3 2024, an estimated $597K.
  • Y-Intercept (HK) first reported a position in Enanta Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Y-Intercept (HK)'s Enanta Pharmaceuticals position peaked at $597K in Q2 2024.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.